Intranasal Delivery of Functionalized Polymeric Nanomaterials to the Brain

Shuai Zha; Ka-Leung Wong; Angelo H. All

doi:10.1002/adhm.202102610

Intranasal Delivery of Functionalized Polymeric Nanomaterials to the Brain

Shuai Zha
, Ka-Leung Wong
, Angelo H. All^*

^*Corresponding author for this work

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

75 Citations (Scopus)

Abstract

Intravenous delivery of nanomaterials containing therapeutic agents and various cargos for treating neurological disorders is often constrained by low delivery efficacy due to difficulties in passing the blood-brain barrier (BBB). Nanoparticles (NPs) administered intranasally can move along olfactory and trigeminal nerves so that they do not need to pass through the BBB, allowing non-invasive, direct access to selective neural pathways within the brain. Hence, intranasal (IN) administration of NPs can effectively deliver drugs and genes into targeted regions of the brain, holding potential for efficacious disease treatment in the central nervous system (CNS). In this review, current methods for delivering conjugated NPs to the brain are primarily discussed. Distinctive potential mechanisms of therapeutic nanocomposites delivered via IN pathways to the brain are then discussed. Recent progress in developing functional NPs for applications in multimodal bioimaging, drug delivery, diagnostics, and therapeutics is also reviewed. This review is then concluded by discussing existing challenges, new directions, and future perspectives in IN delivery of nanomaterials. © 2022 Wiley-VCH GmbH.

Original language	English
Article number	2102610
Number of pages	23
Journal	Advanced Healthcare Materials
Volume	11
Issue number	11
Online published	14 Feb 2022
DOIs	https://doi.org/10.1002/adhm.202102610
Publication status	Published - 8 Jun 2022
Externally published	Yes

Funding

The authors would like to thank the following students—Alison Bartkowski, Ali Al Abdullatif, Kali Barnes, Stuart Bauer, Olivia Choi, Kiersten Colotti, Yinuo Zeng, Andrew Masteller, Ethan Cottrill, and Shengnan Zhang—for their limited contribution in this article. This study has been partially supported by the following grants at the Hong Kong Baptist University: Start‐Up Tier 1 Fund # 21.4531.162640 (PI: A.H.A.), Faculty Seed Fund # 31.4531.179234 (PI: A.H.A.), and Initiation Grant Faculty Niche Research Areas Fund RC‐FNRA‐IG/20‐21/SCI/02 (PI: A.H.A.).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Keywords

brain delivery
functionalized nanomaterials
intranasal delivery
nanomedicines
polymeric nanomaterials
therapeutic nanocarriers

Access Output

10.1002/adhm.202102610

Other Access Options

Check CityUHK Library

Permanent Link

Right click to copy link

Cite this

@article{625ce88cd8a0476a9dbb89ea58b08fb5,

title = "Intranasal Delivery of Functionalized Polymeric Nanomaterials to the Brain",

abstract = "Intravenous delivery of nanomaterials containing therapeutic agents and various cargos for treating neurological disorders is often constrained by low delivery efficacy due to difficulties in passing the blood-brain barrier (BBB). Nanoparticles (NPs) administered intranasally can move along olfactory and trigeminal nerves so that they do not need to pass through the BBB, allowing non-invasive, direct access to selective neural pathways within the brain. Hence, intranasal (IN) administration of NPs can effectively deliver drugs and genes into targeted regions of the brain, holding potential for efficacious disease treatment in the central nervous system (CNS). In this review, current methods for delivering conjugated NPs to the brain are primarily discussed. Distinctive potential mechanisms of therapeutic nanocomposites delivered via IN pathways to the brain are then discussed. Recent progress in developing functional NPs for applications in multimodal bioimaging, drug delivery, diagnostics, and therapeutics is also reviewed. This review is then concluded by discussing existing challenges, new directions, and future perspectives in IN delivery of nanomaterials. {\textcopyright} 2022 Wiley-VCH GmbH.",

keywords = "brain delivery, functionalized nanomaterials, intranasal delivery, nanomedicines, polymeric nanomaterials, therapeutic nanocarriers",

author = "Shuai Zha and Ka-Leung Wong and All, \{Angelo H.\}",

year = "2022",

month = jun,

day = "8",

doi = "10.1002/adhm.202102610",

language = "English",

volume = "11",

journal = "Advanced Healthcare Materials",

issn = "2192-2640",

publisher = "John Wiley \& Sons",

number = "11",

}

TY - JOUR

T1 - Intranasal Delivery of Functionalized Polymeric Nanomaterials to the Brain

AU - Zha, Shuai

AU - Wong, Ka-Leung

AU - All, Angelo H.

PY - 2022/6/8

Y1 - 2022/6/8

N2 - Intravenous delivery of nanomaterials containing therapeutic agents and various cargos for treating neurological disorders is often constrained by low delivery efficacy due to difficulties in passing the blood-brain barrier (BBB). Nanoparticles (NPs) administered intranasally can move along olfactory and trigeminal nerves so that they do not need to pass through the BBB, allowing non-invasive, direct access to selective neural pathways within the brain. Hence, intranasal (IN) administration of NPs can effectively deliver drugs and genes into targeted regions of the brain, holding potential for efficacious disease treatment in the central nervous system (CNS). In this review, current methods for delivering conjugated NPs to the brain are primarily discussed. Distinctive potential mechanisms of therapeutic nanocomposites delivered via IN pathways to the brain are then discussed. Recent progress in developing functional NPs for applications in multimodal bioimaging, drug delivery, diagnostics, and therapeutics is also reviewed. This review is then concluded by discussing existing challenges, new directions, and future perspectives in IN delivery of nanomaterials. © 2022 Wiley-VCH GmbH.

AB - Intravenous delivery of nanomaterials containing therapeutic agents and various cargos for treating neurological disorders is often constrained by low delivery efficacy due to difficulties in passing the blood-brain barrier (BBB). Nanoparticles (NPs) administered intranasally can move along olfactory and trigeminal nerves so that they do not need to pass through the BBB, allowing non-invasive, direct access to selective neural pathways within the brain. Hence, intranasal (IN) administration of NPs can effectively deliver drugs and genes into targeted regions of the brain, holding potential for efficacious disease treatment in the central nervous system (CNS). In this review, current methods for delivering conjugated NPs to the brain are primarily discussed. Distinctive potential mechanisms of therapeutic nanocomposites delivered via IN pathways to the brain are then discussed. Recent progress in developing functional NPs for applications in multimodal bioimaging, drug delivery, diagnostics, and therapeutics is also reviewed. This review is then concluded by discussing existing challenges, new directions, and future perspectives in IN delivery of nanomaterials. © 2022 Wiley-VCH GmbH.

KW - brain delivery

KW - functionalized nanomaterials

KW - intranasal delivery

KW - nanomedicines

KW - polymeric nanomaterials

KW - therapeutic nanocarriers

UR - https://www.scopus.com/pages/publications/85125047655

UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-85125047655&origin=recordpage

U2 - 10.1002/adhm.202102610

DO - 10.1002/adhm.202102610

M3 - RGC 21 - Publication in refereed journal

C2 - 35166052

SN - 2192-2640

VL - 11

JO - Advanced Healthcare Materials

JF - Advanced Healthcare Materials

IS - 11

M1 - 2102610

ER -

Intranasal Delivery of Functionalized Polymeric Nanomaterials to the Brain

Abstract

Funding

UN SDGs

Research Keywords

Access Output

Other Access Options

Permanent Link

Other Files and Links

Fingerprint

Cite this